Tacrolimus and diarrhea: Pathogenesis of altered metabolism
N. Mittal,J. Thompson,Tomoaki Kato,A. Tzakis
DOI: https://doi.org/10.1034/j.1399-3046.2001.005002075.x
2001-04-01
Pediatric Transplantation
Abstract:Isolated from Streptomyces tsukubaensis, tacrolimus is a macrolide lactone that has been used extensively for immunosuppressive therapy in pediatric transplant recipients (1, 2). It is the backbone of immunosuppressive therapy for pediatric solid organ and bone marrow transplant in many centers, including ours. In this month’s issue of Pediatric Transplantation, Frühwirth et al. describe three cases of solid organ transplanted children who suffered increased morbidity caused by a raised trough blood level of tacrolimus in association with rotaviral gastroenteritis (3). A similar observation has been made in two liver transplant infants who exhibited a three-fold rise in the trough levels of tacrolimus and required a reduction in the dose of tacrolimus for less than 1 week during acute diarrheal illness with rotavirus (4). Chronic diarrhea of non-rotaviral etiology has also been shown to be associated with a similar phenomenon in a pediatric renal transplant patient (5). This patient required a three-fold reduction in the dose of tacrolimus during 6 weeks of chronic diarrheal illness and returned to her usual tacrolimus dose when the diarrhea stopped. In patients with intestinal transplant, a sudden rise in the level of tacrolimus has been observed with episodes of rejection (N. Mittal, T. Kato, A. Tzakis, unpubl. obs.). Possible explanations for the rise in blood levels of tacrolimus include hemoconcentration, fasting, increased absorption as a result of increased intestinal permeability, or reduced hepatic metabolism caused by reduced hepatic blood flow or hepatic dysfunction (3–5). Despite the extensive use of tacrolimus for almost a decade, until recently little was known about the important role that the intestine plays in its metabolism (6). Factors involved in oral drug bioavailability – gastric emptying, pH, interaction with food, absorption parameters of the drug (dissolution, lipophilicity, particle size, active uptake by mucosa), and hepatic extraction as ‘first-pass metabolism’ – have traditionally been important considerations. The contributions of intestinal metabolism and Pglycoprotein (P-gp) to the observed changes in the bioavailability of tacrolimus have recently been investigated and these may play dominant roles (6–10).